Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer

Richard L. Schilsky, M. Eileen Dolan, Donna Bertucci, Reginald B. Ewesuedo, Nicholas J. Vogelzang, Sridhar Mani, Lynette R. Wilson, Mark J. Ratain

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

O6-benzylguanine (BG) is a potent inactivator of the DNA repair protein O6-alkylguanine. DNA alkyltransferase (AGT) that enhances sensitivity to nitrosoureas in tumor cell lines and tumor-bearing animals. The major objectives of this study were to define the optimal modulatory dose and associated toxicities of benzylguanine administered alone and in combination with carmustine; to define the maximally tolerated dose and associated toxicities of carmustine administered with benzylguanine and to describe the pharmacokinetics of BG in humans and its effects on AGT depletion and recovery in peripheral blood mononuclear cells. Patients with histologically confirmed advanced solid tumors or lymphoma that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Patients initially received BG as a 1.h i.v. infusion without carmustine. After a 14-day washout (i.e., without therapy) period, patients received BG as a 1-h i.v. infusion followed, 1 h later, by a 15-min i.v. infusion of carmustine. Cycles of chemotherapy were repeated every 6 weeks. Cohorts of patients received BG doses ranging from 10 to 120 mg/m2 and carmustine doses ranging from 13 to 50 mg/m2. Plasma and urine samples were collected and analyzed for BG, and O6-benzyl-8-oxoguanine concentrations and AGT activity was determined in peripheral blood mononuclear cells. There was no toxicity attributable to BG alone at any dose tested. Bone marrow suppression was the primary and dose-limiting toxicity of BG combined with carmustine and was cumulative in some patients. The neutrophil nadir occurred at a median of day 27, with complete recovery in most patients by day 43. Nonhematological toxicity included fatigue, anorexia, increased bilirubin, and transaminase elevation. Recommended doses for Phase H testing are 120 mg/m2 BG given with carmustine at 40 mg/m2. BG rapidly disappeared from plasma and was converted to a major metabolite, O6-benzyl-8-oxoguanine, which has a 2.4-fold higher maximal concentration and 20-fold higher area under the concentration versus time curve than BG. AGT activity in peripheral blood mononuclear cells was rapidly and completely suppressed at all of the BG doses. The rate of AGT regeneration was more rapid for patients treated with the lowest dose of BG but was similar for BG doses ranging from 20-120 mg/m2. In conclusion, coadministration of BG and carmustine is feasible in cancer patients, but the maximal dose of carmustine that can be safely administered with BG is approximately one-third of the standard clinical dose. Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine.

Original languageEnglish (US)
Pages (from-to)3025-3031
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number8
StatePublished - Aug 2000
Externally publishedYes

Fingerprint

Carmustine
Pharmacology
Neoplasms
Blood Cells
Bone Marrow
Clinical Studies
O(6)-benzylguanine
Maximum Tolerated Dose
Anorexia
Transaminases
Tumor Cell Line
Bilirubin
DNA Repair
Fatigue
Regeneration
Lymphoma
Neutrophils
Therapeutics
Pharmacokinetics
Urine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schilsky, R. L., Eileen Dolan, M., Bertucci, D., Ewesuedo, R. B., Vogelzang, N. J., Mani, S., ... Ratain, M. J. (2000). Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clinical Cancer Research, 6(8), 3025-3031.

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. / Schilsky, Richard L.; Eileen Dolan, M.; Bertucci, Donna; Ewesuedo, Reginald B.; Vogelzang, Nicholas J.; Mani, Sridhar; Wilson, Lynette R.; Ratain, Mark J.

In: Clinical Cancer Research, Vol. 6, No. 8, 08.2000, p. 3025-3031.

Research output: Contribution to journalArticle

Schilsky, RL, Eileen Dolan, M, Bertucci, D, Ewesuedo, RB, Vogelzang, NJ, Mani, S, Wilson, LR & Ratain, MJ 2000, 'Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer', Clinical Cancer Research, vol. 6, no. 8, pp. 3025-3031.
Schilsky RL, Eileen Dolan M, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clinical Cancer Research. 2000 Aug;6(8):3025-3031.
Schilsky, Richard L. ; Eileen Dolan, M. ; Bertucci, Donna ; Ewesuedo, Reginald B. ; Vogelzang, Nicholas J. ; Mani, Sridhar ; Wilson, Lynette R. ; Ratain, Mark J. / Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 8. pp. 3025-3031.
@article{3f82e1fd789e4cccb0f30646fdaaac91,
title = "Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer",
abstract = "O6-benzylguanine (BG) is a potent inactivator of the DNA repair protein O6-alkylguanine. DNA alkyltransferase (AGT) that enhances sensitivity to nitrosoureas in tumor cell lines and tumor-bearing animals. The major objectives of this study were to define the optimal modulatory dose and associated toxicities of benzylguanine administered alone and in combination with carmustine; to define the maximally tolerated dose and associated toxicities of carmustine administered with benzylguanine and to describe the pharmacokinetics of BG in humans and its effects on AGT depletion and recovery in peripheral blood mononuclear cells. Patients with histologically confirmed advanced solid tumors or lymphoma that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Patients initially received BG as a 1.h i.v. infusion without carmustine. After a 14-day washout (i.e., without therapy) period, patients received BG as a 1-h i.v. infusion followed, 1 h later, by a 15-min i.v. infusion of carmustine. Cycles of chemotherapy were repeated every 6 weeks. Cohorts of patients received BG doses ranging from 10 to 120 mg/m2 and carmustine doses ranging from 13 to 50 mg/m2. Plasma and urine samples were collected and analyzed for BG, and O6-benzyl-8-oxoguanine concentrations and AGT activity was determined in peripheral blood mononuclear cells. There was no toxicity attributable to BG alone at any dose tested. Bone marrow suppression was the primary and dose-limiting toxicity of BG combined with carmustine and was cumulative in some patients. The neutrophil nadir occurred at a median of day 27, with complete recovery in most patients by day 43. Nonhematological toxicity included fatigue, anorexia, increased bilirubin, and transaminase elevation. Recommended doses for Phase H testing are 120 mg/m2 BG given with carmustine at 40 mg/m2. BG rapidly disappeared from plasma and was converted to a major metabolite, O6-benzyl-8-oxoguanine, which has a 2.4-fold higher maximal concentration and 20-fold higher area under the concentration versus time curve than BG. AGT activity in peripheral blood mononuclear cells was rapidly and completely suppressed at all of the BG doses. The rate of AGT regeneration was more rapid for patients treated with the lowest dose of BG but was similar for BG doses ranging from 20-120 mg/m2. In conclusion, coadministration of BG and carmustine is feasible in cancer patients, but the maximal dose of carmustine that can be safely administered with BG is approximately one-third of the standard clinical dose. Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine.",
author = "Schilsky, {Richard L.} and {Eileen Dolan}, M. and Donna Bertucci and Ewesuedo, {Reginald B.} and Vogelzang, {Nicholas J.} and Sridhar Mani and Wilson, {Lynette R.} and Ratain, {Mark J.}",
year = "2000",
month = "8",
language = "English (US)",
volume = "6",
pages = "3025--3031",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer

AU - Schilsky, Richard L.

AU - Eileen Dolan, M.

AU - Bertucci, Donna

AU - Ewesuedo, Reginald B.

AU - Vogelzang, Nicholas J.

AU - Mani, Sridhar

AU - Wilson, Lynette R.

AU - Ratain, Mark J.

PY - 2000/8

Y1 - 2000/8

N2 - O6-benzylguanine (BG) is a potent inactivator of the DNA repair protein O6-alkylguanine. DNA alkyltransferase (AGT) that enhances sensitivity to nitrosoureas in tumor cell lines and tumor-bearing animals. The major objectives of this study were to define the optimal modulatory dose and associated toxicities of benzylguanine administered alone and in combination with carmustine; to define the maximally tolerated dose and associated toxicities of carmustine administered with benzylguanine and to describe the pharmacokinetics of BG in humans and its effects on AGT depletion and recovery in peripheral blood mononuclear cells. Patients with histologically confirmed advanced solid tumors or lymphoma that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Patients initially received BG as a 1.h i.v. infusion without carmustine. After a 14-day washout (i.e., without therapy) period, patients received BG as a 1-h i.v. infusion followed, 1 h later, by a 15-min i.v. infusion of carmustine. Cycles of chemotherapy were repeated every 6 weeks. Cohorts of patients received BG doses ranging from 10 to 120 mg/m2 and carmustine doses ranging from 13 to 50 mg/m2. Plasma and urine samples were collected and analyzed for BG, and O6-benzyl-8-oxoguanine concentrations and AGT activity was determined in peripheral blood mononuclear cells. There was no toxicity attributable to BG alone at any dose tested. Bone marrow suppression was the primary and dose-limiting toxicity of BG combined with carmustine and was cumulative in some patients. The neutrophil nadir occurred at a median of day 27, with complete recovery in most patients by day 43. Nonhematological toxicity included fatigue, anorexia, increased bilirubin, and transaminase elevation. Recommended doses for Phase H testing are 120 mg/m2 BG given with carmustine at 40 mg/m2. BG rapidly disappeared from plasma and was converted to a major metabolite, O6-benzyl-8-oxoguanine, which has a 2.4-fold higher maximal concentration and 20-fold higher area under the concentration versus time curve than BG. AGT activity in peripheral blood mononuclear cells was rapidly and completely suppressed at all of the BG doses. The rate of AGT regeneration was more rapid for patients treated with the lowest dose of BG but was similar for BG doses ranging from 20-120 mg/m2. In conclusion, coadministration of BG and carmustine is feasible in cancer patients, but the maximal dose of carmustine that can be safely administered with BG is approximately one-third of the standard clinical dose. Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine.

AB - O6-benzylguanine (BG) is a potent inactivator of the DNA repair protein O6-alkylguanine. DNA alkyltransferase (AGT) that enhances sensitivity to nitrosoureas in tumor cell lines and tumor-bearing animals. The major objectives of this study were to define the optimal modulatory dose and associated toxicities of benzylguanine administered alone and in combination with carmustine; to define the maximally tolerated dose and associated toxicities of carmustine administered with benzylguanine and to describe the pharmacokinetics of BG in humans and its effects on AGT depletion and recovery in peripheral blood mononuclear cells. Patients with histologically confirmed advanced solid tumors or lymphoma that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Patients initially received BG as a 1.h i.v. infusion without carmustine. After a 14-day washout (i.e., without therapy) period, patients received BG as a 1-h i.v. infusion followed, 1 h later, by a 15-min i.v. infusion of carmustine. Cycles of chemotherapy were repeated every 6 weeks. Cohorts of patients received BG doses ranging from 10 to 120 mg/m2 and carmustine doses ranging from 13 to 50 mg/m2. Plasma and urine samples were collected and analyzed for BG, and O6-benzyl-8-oxoguanine concentrations and AGT activity was determined in peripheral blood mononuclear cells. There was no toxicity attributable to BG alone at any dose tested. Bone marrow suppression was the primary and dose-limiting toxicity of BG combined with carmustine and was cumulative in some patients. The neutrophil nadir occurred at a median of day 27, with complete recovery in most patients by day 43. Nonhematological toxicity included fatigue, anorexia, increased bilirubin, and transaminase elevation. Recommended doses for Phase H testing are 120 mg/m2 BG given with carmustine at 40 mg/m2. BG rapidly disappeared from plasma and was converted to a major metabolite, O6-benzyl-8-oxoguanine, which has a 2.4-fold higher maximal concentration and 20-fold higher area under the concentration versus time curve than BG. AGT activity in peripheral blood mononuclear cells was rapidly and completely suppressed at all of the BG doses. The rate of AGT regeneration was more rapid for patients treated with the lowest dose of BG but was similar for BG doses ranging from 20-120 mg/m2. In conclusion, coadministration of BG and carmustine is feasible in cancer patients, but the maximal dose of carmustine that can be safely administered with BG is approximately one-third of the standard clinical dose. Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine.

UR - http://www.scopus.com/inward/record.url?scp=0343953050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343953050&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 3025

EP - 3031

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -